Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy for actinic keratosis. Results with imiquimod 3.75%.

Stockfleth E, Gupta G, Peris K, Aractingi S, Dakovic R, Alomar A.

Eur J Dermatol. 2014 Jan-Feb;24(1):23-7. doi: 10.1684/ejd.2014.2265.

PMID:
24589500
2.

Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.

Gupta G, Stockfleth E, Peris K, Aractingi S, Alomar A, Dakovic R, Dirschka T.

J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1840-2. doi: 10.1111/jdv.12697. Epub 2014 Aug 29.

PMID:
25174261
3.

Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions.

Peris K, Stockfleth E, Gupta G, Aractingi S, Dakovic R, Dirschka T, Alomar A.

J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2470-3. doi: 10.1111/jdv.12782. Epub 2014 Oct 28.

PMID:
25351284
4.

Lmax and imiquimod 3.75%: the new standard in AK management.

Stockfleth E.

J Eur Acad Dermatol Venereol. 2015 Jan;29 Suppl 1:9-14. doi: 10.1111/jdv.12824. Review.

PMID:
25470719
5.

Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.

Alomar A, Stockfleth E, Dirschka T, Gupta G, Aractingi S, Dakovic R, Peris K.

J Drugs Dermatol. 2016 Mar;15(3):285-9.

PMID:
26954313
6.

Lmax and imiquimod 3.75% in daily clinical practice.

Gupta G.

J Eur Acad Dermatol Venereol. 2015 Jan;29 Suppl 1:15-8. doi: 10.1111/jdv.12829.

PMID:
25470720
7.
8.
9.

Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment.

Ortonne JP, Gupta G, Ortonne N, Duteil L, Queille C, Mallefet P.

Exp Dermatol. 2010 Jul 1;19(7):641-7. doi: 10.1111/j.1600-0625.2009.01047.x. Epub 2010 Feb 25.

PMID:
20201959
10.

Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.

Gebauer K, Shumack S, Cowen PS.

Br J Dermatol. 2009 Oct;161(4):897-903. doi: 10.1111/j.1365-2133.2009.09260.x. Epub 2009 May 26.

PMID:
19545297
11.

Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials.

Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, Lee JH, Fox TL.

J Am Acad Dermatol. 2004 May;50(5):714-21.

PMID:
15097955
12.
13.
14.

A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses.

Stockfleth E, Meyer T, Benninghoff B, Salasche S, Papadopoulos L, Ulrich C, Christophers E.

Arch Dermatol. 2002 Nov;138(11):1498-502.

PMID:
12437457
15.

Comparative study for the effect of photodynamic therapy, imiquimod immunotherapy and combination of both therapies on 40 lesions of actinic keratosis in Japanese patients.

Tanaka N, Ohata C, Ishii N, Imamura K, Ueda A, Furumura M, Yasumoto S, Kawakami T, Tsuruta D, Hashimoto T.

J Dermatol. 2013 Dec;40(12):962-7. doi: 10.1111/1346-8138.12310. Epub 2013 Oct 22.

PMID:
24147543
16.

Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series.

Tambone S, Fargnoli MC, Capizzi R, Peris K.

G Ital Dermatol Venereol. 2015 Oct 6. [Epub ahead of print]

PMID:
26439591
17.

Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream.

Lee PK, Harwell WB, Loven KH, Phillips TJ, Whiting DA, Andres KL, Lee JH.

Dermatol Surg. 2005 Jun;31(6):659-64.

PMID:
15996416
18.

A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses.

Jorizzo JL, Markowitz O, Lebwohl MG, Bourcier M, Kulp J, Meng TC, Levy S.

J Drugs Dermatol. 2010 Sep;9(9):1101-8.

PMID:
20865842
19.

Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 agonist imiquimod.

Torres A, Storey L, Anders M, Miller RL, Bulbulian BJ, Jin J, Raghavan S, Lee J, Slade HB, Birmachu W.

Br J Dermatol. 2007 Dec;157(6):1132-47. Epub 2007 Oct 18.

PMID:
17944981

Supplemental Content

Support Center